Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Lumosa Therapeutics Co's annualized net income for the quarter that ended in Dec. 2025 was NT$-222.52 Mil. Lumosa Therapeutics Co's average shareholder tangible equity for the quarter that ended in Dec. 2025 was NT$1,550.04 Mil. Therefore, Lumosa Therapeutics Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -14.36%.
The historical rank and industry rank for Lumosa Therapeutics Co's Return-on-Tangible-Equity or its related term are showing as below:
ROCO:6535'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -36 Med: -25.94 Max: 5.5
Current: -20.17
During the past 13 years, Lumosa Therapeutics Co's highest Return-on-Tangible-Equity was 5.50%. The lowest was -36.00%. And the median was -25.94%.
ROCO:6535's Return-on-Tangible-Equity is ranked better than 62.97% of 1199
companies
in the Biotechnology industry
Industry Median: -42.4
vs ROCO:6535: -20.17
Lumosa Therapeutics Co (ROCO:6535) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Lumosa Therapeutics Co Return-on-Tangible-Equity Related Terms
Lumosa Therapeutics Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Lumosa Therapeutics Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumosa Therapeutics Co Return-on-Tangible-Equity Chart
ROCO:6535 vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Lumosa Therapeutics Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumosa Therapeutics Co Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lumosa Therapeutics Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Lumosa Therapeutics Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -14.36% mean?
Lumosa Therapeutics Co (ROCO:6535) has a Return-on-Tangible-Equity of -14.36% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Lumosa Therapeutics Co and its competitors. According to the industry distribution chart, Lumosa Therapeutics Co ranks #444 out of 1199 companies in the Biotechnology industry, placing it in the top 37%.
Is Lumosa Therapeutics Co's Return-on-Tangible-Equity too high?
Lumosa Therapeutics Co's current Return-on-Tangible-Equity is -14.36%. Based on the distribution chart, Lumosa Therapeutics Co ranks #444 out of 1199 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lumosa Therapeutics Co has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lumosa Therapeutics Co's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lumosa Therapeutics Co ranks #444 out of 1199 companies for Return-on-Tangible-Equity. This puts Lumosa Therapeutics Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Lumosa Therapeutics Co and its competitors. Lumosa Therapeutics Co's current Return-on-Tangible-Equity is -14.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumosa Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, Lumosa Therapeutics Co (ROCO:6535) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$131.39, compared to a current price of NT$90.20 — trading 31.3% below its estimated fair value. The current Return-on-Tangible-Equity is -14.36%. Lumosa Therapeutics Co's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Lumosa Therapeutics Co (ROCO:6535), the current Return-on-Tangible-Equity is -14.36% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lumosa Therapeutics Co (ROCO:6535) Overvalued in 2026?
Based on GuruFocus' analysis, Lumosa Therapeutics Co stock appears to be undervalued.
The current stock price of NT$90.20 is trading 31.3% below its estimated GF Value™ of NT$131.39.
GuruFocus considers Lumosa Therapeutics Co to be Significantly Undervalued.
Key valuation signals for ROCO:6535:
Return-on-Tangible-Equity: -14.36%
GF Value™: NT$131.39 vs. price of NT$90.20 (31.3% below fair value)
No single metric tells the full story. See the ROCO:6535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of oncology and Neuroscience. Geographically, it derives a majority of its revenue from Taiwan and also has a presence in Asia, and America. The product pipeline of the company is Neuroscience, which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology, including LT 2003 for Solid Tumor. It generates revenue from sales of goods.
71GF Score
Get the complete analysis for ROCO:6535
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6535 has been successfully added to your 
